# The Effect of Sleep Disorder Diagnosis on Mortality in End-Stage Renal Disease Patients
## 3 Results
\begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline \multirow{2}{*}{**Variable**} & \multirow{2}{*}{**Level**} & \multicolumn{2}{c}{**Mortality**} & \multicolumn{2}{c}{**Simple CPH**} & \multicolumn{2}{c}{**Final CPH**} \\ \cline{3-8}  & & **Dled** & **N = 471.368 (68.5\%)** & **N = 308.574** & **HR = 95\% CD** & **\(p\)-Value** & **HR** & **(95\% CD)** & **\(p\)-Value** \\ \hline Time to Death/ & & & & & & & \\ Follow-Up–mean (SD) & & 2.4 (2.3) & 3.4 (2.2) & & & & \\ \hline Hypersonsonance–\(\alpha\) (\%) & Diagnosis & 2325 (20.7) & 1336 (29.3) & 0.64 (0.61-0.65) & \textless{}0.0001 & 0.81 (0.78-0.84) & \textless{}0.0001 \\ \hline \multirow{2}{*}{Insonemia–\(\alpha\) (\%)} & No Diagnosis & 663,543 (68.5) & 3072,823 (81.5) & 1.00 & & & \\ \hline \multirow{2}{*}{Insonemia–\(\alpha\) (\%)} & Diagnosis & 50,691 (67.48) & 17,121 (25.3) & 0.71 (0.81-0.72) & & & \\ \cline{2-8}  & No Diagnosis & 620,877 (68.1) & 291,453 (32) & 1.00 & & & \\ \hline \multirow{2}{*}{RLS–\(\alpha\) (\%)} & Diagnosis & 200,015 (73.4) & 726 (26.6) & 0.73 (0.73-0.72) & & & \\ \cline{2-8}  & No Diagnosis & 661,535 (68.4) & 301,332 (61.6) & 1.00 & & & \\ \hline \multirow{2}{*}{OSA/CSA–\(\alpha\) (\%)} & Diagnosis & 87,877 (71.3) & 35,344 (2.7) & 0.74 (0.72-0.72) & & & \\ \cline{2-8}  & No Diagnosis & 583,691 (68.1) & 273,231 (31.9) & 1.00 & & & \\ \hline \multirow{2}{*}{Age–mean (SD)} & \multirow{2}{*}{Rack} & \multirow{2}{*}{67.9 (13.3)} & \multirow{2}{*}{58.3 (14.3)} & \multirow{2}{*}{1.03 (0.1034-1.054)} & \multirow{2}{*}{\textless{}0.0001} & \multirow{2}{*}{1.022 (0.132-1.032)} & \textless{}0.0001 \\ \cline{2-8}  & & & & & & & \\ \hline \multirow{2}{*}{Race–\(\alpha\) (\%)} & Other & 31,245 (68.5) & 22,320 (41.5) & 0.67 (0.66-0.68) & & & \\ \cline{2-8}  & White & 47,275 (72.8) & 176,812 (27.2) & 1.00 & & 1.00 & \\ \hline \multirow{2}{*}{See–\(\alpha\) (\%)} & Female & 295,485 (69.1) & 132,205 (05.9) & 0.99 (0.98-0.99) & & & \\ \cline{2-8}  & Male & 370,083 (68.1) & 176,309 (11.9) & 1.00 & & & \\ \hline \multirow{2}{*}{Elasticity–\(\alpha\) (\%)} & Hispanic & 82,676 (58.4) & 86,871 (61.6) & 0.72 (0.71-0.72) & & & \\ \cline{2-8}  & Non-Hispanic & 588,892 (02.2) & 29,292 (85.9) & 1.00 & & & \\ \hline \multirow{2}{*}{Access Type – n (\%)} & Carheter & 562,837 (70.0) & 240,778 (30.4-1.38) & & & & 1.51 (1.80-1.52) & \\ \cline{2-8}  & Graft & 22,785 (69.5) & 10,000 (00.5) & 1.16 (1.14-1.17) & \textless{}0.0001 & 1.20 (1.18-1.22) & \textless{}0.0001 \\ \cline{2-8}  & AVF & 85,946 (98.6) & 57,796 (02.2) & 1.00 & & & 1.00 \\ \hline \multirow{2}{*}{Dialysis Modality–\(\alpha\) (\%)} & Hemodialysis & 67,086 (68.5) & 308,138 (15.5) & 1.57 (0.45-1.71) & & & \\ \cline{2-8}  & Periweek & 582 (57.2) & 436 (42.8) & 1.00 & & & 1.49 (1.37-1.6) & \\ \hline \multirow{2}{*}{CCI–mean (SD)} & \multirow{2}{*}{7.7 (3.8)} & \multirow{2}{*}{5.4 (3.7)} & \multirow{2}{*}{1.008 (0.008-1.009)} & \multirow{2}{*}{\textless{}0.0001} & \multirow{2}{*}{0.990 (0.989-0.991)} & \multirow{2}{*}{0.0001} \\ \cline{2-8}  & & & & & & \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Descriptive statistics by mortality status and simple and final CPH models on mortality.